A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Arcus Biosciences
Start Date
May 27, 2021
End Date
February 28, 2026
Administered By
Duke Cancer Institute
Awarded By
Arcus Biosciences
Start Date
May 27, 2021
End Date
February 28, 2026